SIRT1 and metabolic dysfunction-associated steatotic liver disease: Through the SIRT1/SIRT3 pathway, liraglutide, an acylated glucagon-like peptide-1 (GLP-1) agonist used as an anti-diabetic drug, has been reported to improve NAFLD in HFD mice by improving the mitochondrial architecture, reducing ROS generation, and inducing autophagy [196].